Literature DB >> 17909831

Glottic versus supraglottic tumors: differential molecular profile.

Konstantinos Kourelis1, Theodoros Papadas, Gerasimos Vandoros, Panos Goumas, Georgia Sotiropoulou-Bonikou.   

Abstract

Glottis and supraglottis, although anatomically interconnected, are embryologically distinct. Moreover, squamous cell carcinomas arising from these subsites, differ in terms of epidemiology, risk factors, clinical behaviour and prognosis. This study aims to explore any possible differences between their molecular profiles. We investigated in the two tumor types, the expression of epidermal growth factor receptor (EGFR), nuclear factor-kappaB (NF-kappaB) and retinoid X receptor alpha (RXRalpha), principal signal transducers associated with cancer, as well as cyclooxygenase-2 (COX-2), an enzyme induced in malignant neoplasms. The clinical material includes tumor specimens from 61 patients with laryngeal cancer of glottic or supraglottic origin. Subsite groups were matched for gender, age and histological grade. Paraffin-section immunohistochemistry was performed, to detect the aforementioned molecules. Staining patterns were membranic and cytoplasmic for EGFR, purely cytoplasmic for COX-2, nuclear for RXRalpha and cytoplasmic, as well as nuclear, for NF-kappaB. Intense EGFR and RXRalpha expression was significantly associated with glottic tumor descent (P = 0.011 and 0.001, respectively). No significant relationship was established between neoplasm location and expressions of NF-kappaB, COX-2. Our results show that tumors emerging from the two laryngeal regions, are different with regard to their molecular constitution. Upregulation of EGFR and RXRalpha in carcinomas of the glottis, might be important in the design of subsite-specific chemotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909831     DOI: 10.1007/s00405-007-0441-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  28 in total

1.  The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy.

Authors:  Ernst J Smid; T Rianne Stoter; Elisabeth Bloemena; M Vincent M Lafleur; C René Leemans; Isaac van der Waal; Ben J Slotman; Johannes A Langendijk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-05       Impact factor: 7.038

Review 2.  Epidermal growth factor receptor directed therapy in head and neck cancer.

Authors:  Nicholas W Choong; Ezra E W Cohen
Journal:  Crit Rev Oncol Hematol       Date:  2005-10-03       Impact factor: 6.312

3.  Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.

Authors:  J I Song; M N Lango; J D Hwang; S D Drenning; Q Zeng; W W Lamph; J R Grandis
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

4.  Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions.

Authors:  T Krecicki; M Jeleń; M Zalesska-Krecicka; J Rak; T Szkudlarek; J Jeleń-Krzeszewska
Journal:  Oral Oncol       Date:  1999-03       Impact factor: 5.337

5.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

6.  Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Authors:  John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

7.  Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis.

Authors:  X C Xu; W Y Wong; L Goldberg; S C Baer; J E Wolf; W M Ramsdell; D S Alberts; S M Lippman; R Lotan
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

Review 8.  Retinoid X receptor and its partners in the nuclear receptor family.

Authors:  F Rastinejad
Journal:  Curr Opin Struct Biol       Date:  2001-02       Impact factor: 6.809

9.  Supraglottic and glottic carcinomas: epidemiologically distinct entities?

Authors:  Eduardo De Stefani; Paolo Boffetta; Hugo Deneo-Pellegrini; Paul Brennan; Pelayo Correa; Fernando Oreggia; Alvaro L Ronco; María Mendilaharsu
Journal:  Int J Cancer       Date:  2004-12-20       Impact factor: 7.396

10.  Cyclo-oxygenase 2 expression in laryngeal squamous cell carcinoma and its clinical correlates.

Authors:  Yildirim A Bayazit; Suleyman Buyukberber; Ibrahim Sari; Celalettin Camci; Enver Ozer; Alper Sevinc; Metin Karakok; Muzaffer Kanlikama; Semih Mumbuc
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2004       Impact factor: 1.538

View more
  3 in total

1.  The nicotine dependence phenotype, time to first cigarette, and larynx cancer risk.

Authors:  Joshua E Muscat; Hsiao-Pin Liu; Craig Livelsberger; John P Richie; Steven D Stellman
Journal:  Cancer Causes Control       Date:  2012-02-25       Impact factor: 2.506

2.  Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.

Authors:  Shadan Ali; Sanjeev Banerjee; Jacqueline M Schaffert; Bassel F El-Rayes; Philip A Philip; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2010-05       Impact factor: 4.429

3.  Differential beta-catenin expression between glottic and supraglottic laryngeal carcinoma.

Authors:  Anastasios K Goulioumis; John Varakis; Panos Goumas; Helen Papadaki
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-04-18       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.